


[Products & Services > Catalogue >](#)

PLT VASP/P2Y12

[Presentation](#) [Principle](#) [Download](#) **[Bibliography](#)** [Associated products](#)

Author	Title	Year of edition	Review
Grosdidier C et al.	Effect of CYP2C19*2 and *17 Genetic Variants on Platelet Response to Clopidogrel and Prasugrel Maintenance Dose and Relation to Bleeding Complications	2013	Am J Cardiol.
GREMMEL et al.	Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation	2013	Translational Research
Frelinger A.L et al.	Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance, Diet, Smoking, Co-medications (Including Proton Pump Inhibitors), and Pre-existent Variability in Platelet F	2013	J Am Coll Cardiol
Gaglia MA et al.	Nuisance and alarming bleeding do not correlate with on-treatment platelet reactivity	2013	Cardiovasc Revasc Med.
Wun T et al.	A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease	2013	Journal of Hematology & Oncology
Delavenne X et al.	Investigation of drug-drug interactions between clopidogrel and fluoxetine	2013	Fundam. Clin. Pharmacol.
Kermeis M et al.	Switching Acute Coronary Syndrome Patients From Prasugrel to Clopidogrel	2013	J Am Coll Cardiol Intv
Ferreiro JL et al.	Impact of Prasugrel Reload Dosing Regimens on High On-Treatment Platelet Reactivity Rates in Patients on Maintenance Prasugrel Therapy	2013	J Am Coll Cardiol
Mazur P. et al	Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral arterial disease	2013	Platelets
Nakata T et al	Relationship Between CYP2C19 Loss-of-Function Polymorphism and Platelet Reactivities With Clopidogrel Treatment in Japanese Patients Undergoing Coronary Stent Implantation	2013	Circ. J
Wang X.D et al.	Modified clopidogrel loading dose according to platelet reactivity monitoring in patients carrying ABCB1 variant alleles in patients with clopidogrel resistance	2012	Eur J Int Med
Kobsar A et al.	The thrombin inhibitors, hirudin und Refludan®, activate the soluble guanylyl cyclase and the cGMP pathway in washed human platelets	2012	Thromb Haemost.
Jeong YH. et al.	High on-treatment platelet reactivity assessed by various platelet function tests: Is the consensus-defined cutoff of VASP-P platelet reactivity index too low?"	2012	J Thromb Haemost
Frelinger A.L. et al,	A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers	2012	J. Am. Coll. Cardiol.
Reny J.L. et al.	Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis	2012	J Thromb Haemost
Tello-Montoliu A.et al.	Pharmacodynamic Effects of Prasugrel Dosing Regimens in Patients on Maintenance Prasugrel Therapy	2012	J. Am. Coll. Cardiol.
Ferreiro J.L.et al.	Impact of Adjunctive Cilostazol Therapy Versus High Maintenance Dose of Clopidogrel in Suboptimal Responders With Diabetes Mellitus	2012	Rev Esp Cardiol.
Aradi D et al.	Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity	2012	Eur J Clin Invest.
Yokoi H et al.	Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention	2012	Thromb Res
Bonello L. et al	Relationship between post-treatment platelet reactivity and ischemic and bleeding events at one year follow-up in patients receiving prasugrel	2012	J Thromb Haemost
Liang Y et al	Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin	2012	J Thromb Thrombolysis
Bonello L. et al	Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction	2012	Thromb Haemost.
Bonello L. et al	Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade	2012	Thromb Res
Erlinge D. et al	Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Body-Weight Patients	2012	J Am Coll Cardiol
Suryadevara S. et al	Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus	2012	Thromb Haemost
Cuisset T. et al	CYP2C19*2 and *17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated With Prasugrel After Acute Coronary Syndrome	2012	J Am Coll Cardiol Intv
Chang H et al	Modified Diadenosine Tetraphosphates with Dual Specificity for P2Y1 and P2Y12 are Potent Antagonists of ADP-induced Platelet Activation	2012	J Thromb Haemost
Tello-Montoliu A et al	Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus	2012	J Thromb Thrombolysis
Morel et al	The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: roles of white blood cell count and body weight.	2012	Thromb Haemost.
Yano H et al	Influence of Omeprazole and Famotidine on the Antiplatelet Effects of Clopidogrel in Addition to Aspirin	2012	Circ J.
Kalantzi KI et al.	Clopidogrel differentially affects platelet-mediated thrombosis and inflammatory response in patients with acute coronary syndromes	2011	J Thromb Haemost.
Petrucci G et			

al.	Prostaglandin E2 Differentially Modulates Human Platelet Function through the Prostanoid EP2 and EP3 Receptors	2011	JPET
Morel O et al.	Cardiovascular Mortality in Chronic Kidney Disease Patients Undergoing Percutaneous Coronary Intervention Is Mainly Related to Impaired P2Y12 Inhibition by Clopidogrel	2011	J. Am. Coll. Cardiol.
Ueno M et al.	Functional profile of the platelet P2Y12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease	2011	Thromb Haemost
Angiolillo DJ et al.	Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy	2011	Thromb Haemost
Freynhofer MK et al.	Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events	2011	Thromb Haemost
Mani H. et al.	Platelet function testing in hirudin and BAPA anticoagulated blood	2011	Clin Chem Lab Med
Szymezak J. et al.	High on-clopidogrel platelet reactivity: Genotyping can help to optimize antiplatelet treatment	2011	Thromb Res
Pettersen A. et al.	The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel	2011	Thrombosis Journal
Prüller F. et al.	Low platelet reactivity is recovered by transfusion of stored platelets: A healthy volunteer in vivo study	2011	J Thromb Haemost
Wang XD. et al.	Modifying Clopidogrel Maintenance Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Improves Clinical Outcome in Patients With Clopidogrel Resistance	2011	Clin. Cardiol.
Frelinger A. et al.	Clopidogrel pharmacokinetics and pharmacodynamics vary widely, independent of CYP2C19 polymorphisms, diet, smoking, proton pump inhibitors and other co-medications	2011	J. Am. Coll. Cardiol.
Angiolillo DJ et al.	Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy	2011	Thromb Haemost.
Storey RF et al.	Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared to clopidogrel in patients with high antiplatelet responses	2011	J Thromb Haemost
Fontana P et al.	Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study	2011	J Thromb Haemost
Fernando H et al.	Randomised Double Blind Placebo Controlled Crossover Study to Determine the Effects of Esomeprazole on Inhibition of Platelet Function by Clopidogrel	2011	J Thromb Haemost
Bonello L et al.	High On-Treatment Platelet Reactivity After Prasugrel Loading Dose and Cardiovascular Events After Percutaneous Coronary Intervention in Acute Coronary Syndromes	2011	J. Am. Coll. Cardiol.
Ferreiro JL et al.	Pharmacodynamic evaluation of pentaprazole therapy on clopidogrel effect	2011	Circ Cardiovasc Interv.
Ferreiro JL et al.	Impact of Adjunctive Cilostazol Therapy Versus High Maintenance Dose of Clopidogrel in Suboptimal Responders With Diabetes Mellitus	2011	Rev Esp Cardiol.
Ueno M et al.	Impact of Pentoxifylline on Platelet Function Profiles in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel	2011	J Am Coll Cardiol Interv
Bliden KP et al.	The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: Combined analysis of the ONSET/OFFSET and RESPOND studies	2011	Am Heart J.
Grdinic A et al.	PCI and clopidogrel: antiplatelet responsiveness and patient characteristics	2011	Acta Cardiol.
Gaglia MA Jr et al.	Relation of Body Mass Index to On-Treatment (Clopidogrel + Aspirin) Platelet Reactivity	2011	Am J Cardiol.
Mega J.L et al.	Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease	2011	JAMA
Tsoumani ME	Antiplatelet Efficacy of Long-Term Treatment With Clopidogrel Besylate in Patients With a History of Acute Coronary Syndrome: Comparison With Clopidogrel Hydrogen Sulfate	2011	Angiology
Motovska Z et al.	Optimal pretreatment timing for high load dosing (600 mg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectiveness	2010	Int J Cardiol.
Palmerini T. et al,	A randomised study comparing the antiplatelet and antiinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: Results from the DOUBLE study	2010	Thromb Res
Bonello L et al.	Impact of loading dose adjustment on platelet reactivity in homozygotes of the 2C19 2* loss of function polymorphism	2010	Int J cardiol.
Bonello L et al.	Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients	2010	Thromb Res.
von Beckerath N et al.	Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet vasodilator-stimulated phosphoprotein flow cytometry	2010	Blood Coagulation and Fibrinolysis
Gurbel PA et al.	The Effect of Elinogrel on High Platelet Reactivity During Dual Antiplatelet Therapy and the Relation to CYP 2C19*2 Genotype:First Experience in Patients	2010	J Thromb Haemost.
Bellemain-Appaix A et al.	Slow Response to Clopidogrel Predicts Low Response	2010	J. Am. Coll. Cardiol.
Metzmer H et al.	Premature preoperative discontinuation of antiplatelet drug therapy in cardiovascular risk patients: a preliminary study on the role of P2Y12 receptor monitoring	2010	Eur J Anaesthesiol.
Cuisset T et al.	Clopidogrel response: Head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting	2010	Archives of Cardiovascular Disease
Gurbel PA et al.	Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies. The RESPOND Study	2010	Circulation
Small DS et al.	Pharmacodynamics and Pharmacokinetics of Single Doses of Prasugrel 30 mg and Clopidogrel 300 mg in Healthy Chinese and White Volunteers: An Open-Label Trial	2010	Clin Ther.
Flierl U et al.	The novel P2Y12 antagonist AZD6140 rapidly and reversibly reduces platelet activation in diabetic rats	2010	Thromb Res
Bouman HJ et al.	Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel	2010	J Thromb Haemost.
Gajos G et al.	Effects of Polyunsaturated Omega-3 Fatty Acids on Responsiveness to Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention	2010	J. Am. Coll. Cardiol.
El Ghannudi S	Impact of P2Y12 Inhibition by Clopidogrel on Cardiovascular Mortality in Unselected Patients Treated by Percutaneous Coronary Angioplasty	2010	J Am Coll Cardiol Interv
Bonello L et al.	Clopidogrel Loading Dose Adjustment According to Platelet Reactivity Monitoring in Patients Carrying the 2C19 2* Loss of Function Polymorphism	2010	J. Am. Coll. Cardiol.

Delavenne X et al.	Is there really a relationship between the plasma concentration of the active metabolite of clopidogrel and the results of platelet function tests?	2010	J Thromb Haemost.Â
Aradi D et al.	Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition	2010	Platelets
Zighetti ML et al.	Usefulness of a flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of patients with genetic defects of the platelet P2y12 receptor for ADP	2010	J Thromb Haemost.Â
Bonello L et al.	Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate	2010	J. Am Coll Cardiol.
Storey RF et al.	Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary Syndromes The PLATO (PLATElet inhibition and patient Outcomes) PLATELET Substudy	2010	J. Am. Coll. Cardiol.
Angiolillo DJ et al.	Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary Syndromes Results of the SWAP (Switching Anti Platelet) Study	2010	J. Am. Coll. Cardiol.
Bonello L et al.	Level of P2Y12-ADP receptor blockade during percutaneous coronary intervention predicts the extent of endothelial injury, assessed by CEC measurement	2010	J. Am. Coll. Cardiol.
Bjellanda TW et al.	Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest	2010	Resuscitation
Fu Q et al.	Comparison of platelet P2Y12 ADP receptor mediated pathway inhibition in triple versus dual antiplatelet therapy as assessed by VASP phosphorylation in Japanese patients undergoing coronary stenting	2010	Int Heart J.
Fontana P et al.	Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study	2010	J Thromb Haemost.
Ferreiro JL et al.	Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake	2010	Circ Cardiovasc Interv.
Tantry U et al.	First Analysis of the Relation Between CYP2C19 Genotype and Pharmacodynamics in Patients Treated With Ticagrelor Versus Clopidogrel. The ONSET/OFFSET and RESPOND Genotype Studies	2010	Circ Cardiovasc Genet.
Osmancik P et al.	A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction*	2010	Catheter Cardiovasc Interv.
Bonello L et al.	Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Prevent Acute and Subacute Stent Thrombosis	2009	Am J Cardiol.
Lortie E. et al.	Clopidogrel induces an acute hemostatic deficit and increases intra abdominal bleeding in rabbits	2009	Thromb Res
Siller-Matula JM et al.	The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation	2009	Thromb Res
Bonello L et al.	Emergence of the Concept of Platelet Reactivity Monitoring of Response to Thienopyridines	2009	Heart
Hogberg C. et al .	Mild hypothermia does not attenuate platelet aggregation and may even increase ADP-stimulated platelet aggregation after clopidogrel treatment	2009	Thrombosis Journal
Cuisset T et al.	Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response	2009	Thromb Res.
Varenhorst C et al.	Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease	2009	Eur Heart J
Motovska Z et al.	High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial	2009	Blood Coagul Fibrinolysis
Michelson A. et al	Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial	2009	European Heart Journal
Cuisset T et al.	Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non ST-elevation acute coronary syndrome	2009	EuroIntervention
Aleil B. et al.	CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring	2009	J Thromb Haemost
Siller-Matula JM et al.	Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel	2009	Am Heart J
Cuisset T et al.	Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose	2009	J. Am. Coll. Cardiol.
Alstr�m U et al.	Platelet inhibition assessed with VerifyNow, flow cytometry and PlateletMapping in patients undergoing heart surgery	2009	Thromb Res
Siller-Matula JM et al.	Cross validation of the Multiple Electrode Aggregometry	2009	Thromb Haemost.
Gremmel T et al.	Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation	2009	Thromb Haemost.
James S et al.	Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATElet inhibition and patient Outcomes (PLATO) trial	2009	Am Heart J
Gurbel PA and Tantry U.	Selecting Optimal Antiplatelet Therapy Based on Platelet Function Monitoring in Patients With Coronary Artery Disease	2009	Curr Treat Op Cardio Med
Frere C et al.	CYP2C19*17 Allele is associated with Better Platelet Response to Clopidogrel in patients admitted for Non-ST Acute Coronary Syndrome	2009	J Thromb Haemost.
Motovska Z et al.	Clopidogrel resistance Live" - the risk of stent thrombosis should be evaluated before procedures	2009	Thrombosis J
Motovska Z et al.	Factors Influencing Clopidogrel Efficacy in Patients With Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention: Statin's Advantage and the Smoking	2009	J Cardiovasc Pharmacol
Wallentin L et al.	Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease	2008	European Heart Journal
Sbrana S et al.	Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation	2008	Cytometry Part B
Gilard M. et al.	Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin: The Randomized, Double-Blind OCLA (Omeprazole CLopidogrel Aspirin) Study	2008	J. Am. Coll. Cardiol.
Gurbel PA et al.	Omeprazole A Possible New Candidate Influencing the Antiplatelet Effect of Clopidogrel	2008	J. Am. Coll. Cardiol.
Frere C et al.	Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome	2008	Am J Cardiol.
Angiolillo DJ et al.	Functional Effects of High Clopidogrel Maintenance Dosing in Patients With Inadequate Platelet Inhibition on Standard Dose Treatment	2008	Am J Cardiol.
Bonello L et	Adjusted Clopidogrel Loading Doses According to VASP Phosphorylation Index Decrease Rate of Major Adverse		

al.	Cardiovascular Events in Patients With Clopidogrel Resistance: A Multicentre Randomized Prospective Study	2008	J. Am. Coll. Cardiol.
Jakubowski J et al.	A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry	2008	Thromb Haemost.
Yano Y et al.	Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in dual-antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad	2008	Eur Heart J.
Umemura K et al.	The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics to an active metabolite of clopidogrel in healthy subjects	2008	J Thromb Haemost
Bonello L et al.	A threshold of platelet reactivity for ischaemic events?	2008	Eur Heart J.
Bonello L et al.	Two strategies of clopidogrel loading dose to decrease the frequency of clopidogrel resistance in patients undergoing percutaneous coronary intervention	2008	Thromb Res
Michelson A et al.	P2Y12 Antagonism: Promises and Challenges	2008	ATVB
Angiolillo DJ et al.	A randomized study assessing the impact of clobazepam on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study	2008	Eur Heart J.
Schäfer A et al.	ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay	2008	Thromb Haemost
Siller-Matula JM et al.	Calcium-Channel Blockers Reduce the Antiplatelet Effect of Clopidogrel	2008	J. Am. Coll. Cardiol.
Morel O et al.	Residual prothrombotic status in low responder patients to clopidogrel identified by Vasodilator-Stimulated Phosphoprotein Phosphorylation (VASP) analysis?	2008	Thromb Haemost
Djukanovic N. et al.	Thienopyridine Resistance Among Patients Undergoing Intracoronary Stent Implantation and Treated With Dual Antiplatelet Therapy: Assessment of Some Modifying Factors	2008	J Pharmacol Sci
De Miguel A et al.	Clinical implications of clopidogrel resistance	2008	Thromb Haemost.
Weber AA et al.	Methods to Evaluate the Pharmacology of Oral Antiplatelet Drugs	2008	Herz
Aleil B al.	Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention"	2008	J Am Coll Cardiol Intv
Erlinge D et al.	Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo	2008	J. Am. Coll. Cardiol.
Cayla G et al.	Flow cytometric assessment of vasodilator-stimulated phosphoprotein: Prognostic value of recurrent cardiovascular events after acute coronary syndromes	2008	Arch Cardiovasc Dis.
Aleil B et al.	Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogrel: a report of three cases	2007	J Thromb Haemost
Angiolillo DJ et al.	Randomized comparison of a high clopidogrel maintenance dose in patients with Diabetes mellitus and coronary artery disease	2007	Circulation
van Werkum et al.	The flow cytometric VASP assay can be used to determine the effectiveness of clopidogrel in patients treated with Abciximab	2007	J Thromb Haemost
Cuisset T et al.	Lack of association between the 807C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome	2007	Thromb Haemost.
Mueller Tet al.	Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate® analyzer -comparison with two flow cytometric methods"	2007	Thromb Res
Cuisset T. et al.	Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome	2007	Thromb Res
Bonello L et al.	VASP phosphorylation analysis prior to percutaneous coronary intervention for exclusion of post-procedural major adverse cardiovascular events	2007	J Thromb Haemost
Cattaneo M et al.	Platelet P2 receptors: old and new targets for antithrombotic drugs	2007	Cardiovascular Therapy
Gurbel PA et al.	Assessment of clopidogrel responsiveness : measurements of maximum platelet aggregation, final platelet aggregation and their correlation with Vasodilator stimulated phosphoprotein in resistant patients	2007	Thromb Res
Schumacher WA et al.	Biomarker optimization to track antithrombotic and hemostatic effects of clopidogrel	2007	J Pharmacol Exp Ther.
De Gaetano and Cerletti.	Platelet function, antiplatelet therapy and clinical outcomes : to test or not to test ?	2007	J Thromb Haemost
Paniccia R et al.	Different methodologies for evaluating the effect of clopidogrel on platelet function in high risk coronary artery disease patients	2007	J Thromb Haemost
Dropinski et al.	The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin	2007	Thromb Haemost.
Fontana P et al.	Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness	2007	Thromb Haemost.
Morel O et al.	Impaired platelet responsiveness to clopidogrel identified by flow cytometric VASP phosphorylation in patients with subacute stent thrombosis	2007	Thromb Haemost.
Frere C et al.	ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome	2007	Thromb Haemost.
Gurbel PA et al.	Platelet function monitoring in patients with coronary artery disease	2007	JACC
Blindt R et al.	The Significance of Vasodilator-Stimulated Phosphoprotein for Risk Stratification of Stent Thrombosis	2007	Thromb Haemost.
Eli Lev et al.	Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease	2007	Am Heart J
Schäfer A et al.	Late thrombosis of a drug-eluting stent during combined anti-platelet therapy in a clopidogrel nonresponsive diabetic patient: Shall we routinely test platelet function ?	2007	Thromb Haemost.
Wiviott SD et al.	Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention	2007	Circulation
Montalescot G et al.	A randomized comparison of high clopidogrel loading doses in patients with non -ST-Segment elevation Acute coronary syndromes	2006	JACC
Gilart M. et al.	Influence of omeprazole on the anti platelet action of clopidogrel associated to aspirin	2006	J Thromb Haemost
Bura A et al.	Role of the P2Y12 gene polymorphism in the platelet responsiveness to clopidogrel in healthy subjects	2006	J Thromb Haemost
Hulot JS et al.	Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in	2006	Blood

	healthy subjects		
Cauwenberghs et al.	Plasma ectonucleotidases prevent desensitization of purinergic receptors in stored platelets: importance for platelet activity during thrombus formation	2006	Transfusion
Pampuch et al.	Comparison of VASP phosphorylation assay to light transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor	2006	Thromb Haemost.
Gurbel PA and Tantry U	Drug insight : clopidogrel responsiveness	2006	Nat Clin Pract Cardiovasc Med
Aleil B et al.	Flow cytometry analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases	2005	J Thromb Haemost
Aleil B et al.	High stability of blood samples for flowcytometric analysis of VASP phosphorylation to measure the clopidogrel responsiveness in patients with coronary artery disease	2005	Thromb Haemost.
Aleil B and Gachet C	Inter-individual variability in the response to clopidogrel	2005	Archives des Maladies du Coeur et des Vaisseaux
Gurbel PA et al.	Clopidogrel Effect on Platelet REactivity in Patients With Stent Thrombosis, Results of the CREST Study	2005	J Am Coll Cardiol
Barragan P et al.	Resistance to thienopyridines : clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation	2003	Cathet Cardiovasc Intervent